Bet Bromodomain Inhibitor Zen-3694
Metastatic Prostate Carcinoma
Explore 229 assets in Metastatic Prostate Carcinoma →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06922318CT.gov The COSMYC Trial (COmbined Suppression of MYC) | — | Recruiting | — | — | — |
NCT04986423CT.gov ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT02711956CT.gov A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02705469CT.gov A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bet Bromodomain Inhibitor Zen-3694 (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | B · 59 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Bet Bromodomain Inhibitor Zen-3694
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 60 |
| Triple-Negative Breast Carcinoma | — | P2 | B · 60 |
| Metastatic Malignant Neoplasm | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bet Bromodomain Inhibitor Zen-3694 in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bet-bromodomain-inhibitor-zen-3694-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →